2 months ago
Tecartus MCL(Mantle cell lymphoma)
Tecartus MCL(Mantle cell lymphoma) Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma that arises from the “mantle zone” of the lymph nodes. It commonly af...
2 months ago
2 months ago
Tecartus Mantle Cell Lymphoma
Tecartus Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma that affects B cells, which are a type of white blood cell. Despite advances i...
2 months ago
Tecartus Indication: A Comprehensive Overview
Tecartus Indications: A Comprehensive Overview Tecartus (brexucabtagene autoleucel) is a groundbreaking CAR-T cell therapy developed for specific hematological malignancies. Approved by the FDA for...
2 months ago
Tecartus FDA Approval Date
Tecartus FDA Approval Date On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy de...
2 months ago
Tecartus CAR-T: Revolutionizing the Treatment Landscape for Hematological Malignancies
Tecartus CAR-T: Revolutionizing the Treatment Landscape for Hematological Malignancies In the field of oncology, the development of targeted therapies has revolutionized the way we approach cancer ...
2 months ago
Chinese CAR-T Therapy: A New Frontier in Treating Systemic Lupus Erythematosus
Chinese CAR-T Therapy: A New Frontier in Treating Systemic Lupus Erythematosus Systemic Lupus Erythematosus #Lupus #LupusErythematosus #SystemicLupusErythematosus #CART #CARTTherapy #SLE Recently...
2 months ago
**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China**
**Chinese Biopharmaceuticals: Ushering in a New Era in Nasopharyngeal Carcinoma Treatment, EBV-Specific CAR-T Injection Approved for Phase II Clinical Trials in the US and China** Nasopharyngeal C...
2 months ago
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After r...
2 months ago
Tecartus Approval History
Tecartus Approval History Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy, has revolutionized the treatment landscape for certain types of cancer. Developed by Kite Pharma...
2 months ago
**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau**
**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau** Cervical Cancer On August 6, 2024, Zai Lab proudly announced the approval of TIVDAK® (tisotumab vedotin-tftv) in Macau, mar...
2 months ago
Tecartus Approval Date
Tecartus Approval Date On July 24, 2020, the US Food and Drug Administration (FDA) granted accelerated approval to Tecartus (brexucabtagene autoleucel), a groundbreaking CAR-T cell therapy, for the...
2 months ago
Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment
Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment AML In the field of hematological malignancies, the treatment of acute myeloid leukemia (AML...